AstraZeneca Takes Out ZS Pharma, Bodes Well for Relypsa

AstraZeneca (AZN) will buy ZS Pharma (ZSPH) for $2.7 billion in cash, or $90 per share – a 42% premium to yesterday’s close. Recall that Relypsa (RLYP) and its Veltassa (patiromer) are neck and neck as new entrants to the hyperkalemia market. Relypsa is up 10% on the news this morning.